Key Segments:
By Component
-
Software
-
Services
By AI Technology
-
Machine Learning
-
Deep Learning
-
Natural Language Processing
-
Generative AI
-
Others
By Application
-
Target Identification and Validation
-
Molecule Design and Optimization
-
Preclinical Testing
-
Drug Repurposing
-
Others
By Deployment Model
-
Cloud-Based
-
On-Premise
-
Hybrid
By End User
-
Pharmaceutical Companies
-
Biotechnology Companies
-
Contract Research Organizations
-
Academic and Research Institutes
-
Others
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players include Isomorphic Labs, Insilico Medicine, Recursion Pharmaceuticals, Inc., BenevolentAI, and Atomwise, Inc., among other AI-native drug discovery companies.
Continued maturation of AI-discovered drug candidates through clinical trials and continued expansion of pharmaceutical partnership depth and scale represent the primary opportunities.
Growth is primarily driven by growing pharmaceutical demand to reduce drug discovery timelines and research and development costs, combined with increasing adoption of generative AI and foundation models.
By Component, Software dominated the market in 2025, reflecting its role as the foundational purchase for pharmaceutical AI research capability.
North America dominated the market with a 39.85% share in 2025, supported by the concentration of the world's largest pharmaceutical and AI-native biotechnology companies.
